Todd Foley is a Managing Director at MPM Capital. He focuses on biotech investments and serves on a number of MPM portfolio company boards, including Repare Therapeutics, CODA Biotherapeutics, Chiasma (CHMA), Entrada Therapeutics, Iconic Therapeutics, Rhythm Therapeutics (RYTM), Semma Therapeutics and Tetherex Therapeutics. Todd also manages MPM’s strategic investment relationship with Novartis (NVS), which MPM believes has been one of the industry’s longest standing and most prolific collaborations between venture capital investors and pharma, having committed $200 million to over a dozen companies in the biotech and healthcare IT space under a variety of creative joint equity/strategic deal structures. Prior to MPM, Todd’s career in the life science industry included Business Development at Genentech (Roche) and management consulting with Arthur D. Little. He holds a BS in Chemistry from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.